Fig 1.
The thrombodynamics method principle.
(A) The photos of fibrin clot growth are shown for normal plasma and in LMWH presence (0.08 IU/ml). The edge of the activator on the top of the pictures is covered with immobilized tissue factor. Clot starts growing from the edge of the activator to the bulk of the plasma. The process of fibrin clot formation is recorded in a time-lapse video microscopy mode by means of dark-field light scattering method. The obtained series of photos shows how the size of fibrin clot changes over time. (B) Plot of clot size versus time in normal plasma (black line) and in LMWH presence (0.1 IU/ml) representing the principle of the parameter V calculation. (C) The in vitro heparin dose dependency for V in the presence of UFH or LMWH in plasma of healthy volunteers. Means and SEM were shown (n = 10).
Table 1.
Characteristics of patients.
Fig 2.
APTT vs TD parameters before heparin treatment.
(A) APTT and (B) V in TD before heparin treatment in groups: healthy volunteers (control group), group 1, group 2 and group 3. The box plots indicate the following parameters: the mean value (the dot inside the box), the median (the horizontal line inside the box), the 25th and 75th percentiles (the bottom and top of the box, respectively) and the 5th and 95th percentiles (the ends of the whiskers). * indicates a significant difference from healthy volunteers group (p<0.01, Mann-Whitney test).
Fig 3.
ROC curves for APTT (gray lines) and V in TD (black lines) for treatment with LMWH (group 1) at the Point 1 (A) and Point 2 (B) or UFH (group 1) at the Point 1 (C) and Point 2 (D) and prophylactics with LMWH (group 2) at the Point 1 (E) and Point 2 (F) or UFH (group 3) at Point 1 (G). Data of the same patients before the first heparin injection were used as controls.
Fig 4.
Heparin effect on anti-Xa vs TD.
ROC curves for anti-Xa (gray lines) and V in TD (black lines) for treatment with LMWH (group 1) at Point 1 (A) and Point 2 (B) and prophylaxis with LMWH (group 2) at Point 1 (C) and Point 2 (D). Data of the same patients before the first heparin injection were used as controls.
Fig 5.
TGT vs TD before heparin treatment.
(A) ETP in TGT and (B) V in TD before heparin treatment in groups: healthy volunteers (control group), group 1, group 2) and group 3. The box plots indicate the following parameters: the mean value (the dot inside the box), the median (the horizontal line inside the box), the 25th and 75th percentiles (the bottom and top of the box, respectively) and the 5th and 95th percentiles (the ends of the whiskers). * indicates a significant difference from healthy volunteers group (p<0.01, Mann-Whitney test).
Fig 6.
ROC curves for ETP in TGT (gray lines) and V in TD (black lines) for treatment with UFH (group 1) at Point 1 (A) and Point 2 (B) and prophylaxis with LMWH (group 2) at Point 1 (C) and Point 2 (D) or UFH (group 3) at Point 1 (E). Data of the same patients before the first heparin injection were used as controls.
Fig 7.
TEG vs TD before heparin treatment.
(A) alpha in TEG and (B) V in TD before heparin treatment in groups: healthy volunteers (control group), group 2 and group 3. The box plots indicate the following parameters: the mean value (the dot inside the box), the median (the horizontal line inside the box), the 25th and 75th percentiles (the bottom and top of the box, respectively) and the 5th and 95th percentiles (the ends of the whiskers). * indicates a significant difference from healthy volunteers group (p<0.01, Mann-Whitney test).
Fig 8.
ROC curves for alpha in TEG (gray lines) and V in TD (black lines) for prophylaxis with LMWH (group 2) at Point 1 (A) and Point 2 (B) or UFH (group 3) at Point 1 (C). Data of the same patients before the first heparin injection were used as controls.